These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. LeWitt PA; Jennings D; Lyons KE; Pahwa R; Rabinowicz AL; Wang J; Guarnieri M; Hubble JP; Murck H Mov Disord; 2009 Jul; 24(9):1319-24. PubMed ID: 19412946 [TBL] [Abstract][Full Text] [Related]
23. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients. Senek M; Nyholm D; Nielsen EI Eur J Clin Pharmacol; 2018 Oct; 74(10):1299-1307. PubMed ID: 29882153 [TBL] [Abstract][Full Text] [Related]
25. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa. Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816 [TBL] [Abstract][Full Text] [Related]
26. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. Stocchi F; Barbato L; Nordera G; Bolner A; Caraceni T J Neural Transm (Vienna); 2004 Feb; 111(2):173-80. PubMed ID: 14767720 [TBL] [Abstract][Full Text] [Related]
27. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Nutt JG; Woodward WR; Anderson JL Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849 [TBL] [Abstract][Full Text] [Related]
28. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Cedarbaum JM; Kutt H; McDowell FH Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762 [TBL] [Abstract][Full Text] [Related]
29. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa. Deleu D; Ebinger G; Michotte Y Eur J Clin Pharmacol; 1991; 41(5):453-8. PubMed ID: 1761073 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Müller T Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910 [TBL] [Abstract][Full Text] [Related]
32. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292 [TBL] [Abstract][Full Text] [Related]
33. Effect of supplemental carbidopa on bioavailability of L-dopa. Cedarbaum JM; Kutt H; Dhar AK; Watkins S; McDowell FH Clin Neuropharmacol; 1986; 9(2):153-9. PubMed ID: 3085927 [TBL] [Abstract][Full Text] [Related]
34. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690 [TBL] [Abstract][Full Text] [Related]
35. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. Chan PL; Nutt JG; Holford NH J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):307-31. PubMed ID: 16320098 [TBL] [Abstract][Full Text] [Related]
36. The promise and limitations of controlled-release oral levodopa administration. Cedarbaum JM Clin Neuropharmacol; 1989 Jun; 12(3):147-66. PubMed ID: 2663145 [No Abstract] [Full Text] [Related]
38. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. Kempster PA; Frankel JP; Bovingdon M; Webster R; Lees AJ; Stern GM J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):718-23. PubMed ID: 2501456 [TBL] [Abstract][Full Text] [Related]
39. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). Jorga KM; Nicholl DJ Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160 [TBL] [Abstract][Full Text] [Related]
40. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens. Nagashima Y; Kondo T; Sakata M; Koh J; Ito H J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]